- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal Antibody-Based Therapies for Myasthenia Gravis
Authors
Keywords
-
Journal
BIODRUGS
Volume 34, Issue 5, Pages 557-566
Publisher
Springer Science and Business Media LLC
Online
2020-09-11
DOI
10.1007/s40259-020-00443-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
- (2020) Eric R. Fedyk et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
- (2020) James F. Howard et al. JAMA Neurology
- Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
- (2020) Karissa L. Gable et al. Frontiers in Immunology
- Update on immune‐mediated therapies for myasthenia gravis
- (2020) Ali Aamer Habib et al. MUSCLE & NERVE
- Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
- (2020) Mariapaola Marino et al. Frontiers in Immunology
- Complement Inhibitor Therapy for Myasthenia Gravis
- (2020) Khaled Albazli et al. Frontiers in Immunology
- The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model
- (2020) Xiangyang Zhang et al. JOURNAL OF IMMUNOLOGY
- Tackling the cytokine storm in COVID-19, challenges and hopes
- (2020) Shifaa M. Abdin et al. LIFE SCIENCES
- M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model
- (2019) Sucharita Roy et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
- (2019) James F. Howard et al. NEUROLOGY
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
- (2019) Sean J. Pittock et al. NEW ENGLAND JOURNAL OF MEDICINE
- New therapies for systemic lupus erythematosus — past imperfect, future tense
- (2019) Grainne Murphy et al. Nature Reviews Rheumatology
- Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility
- (2019) Hui Deng et al. BMC Medical Genetics
- Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review
- (2019) Jayne L. Chamberlain et al. JOURNAL OF NEUROLOGY
- Myasthenia gravis: Historical achievements and the “golden age” of clinical trials
- (2019) Tam M. Nguyen-Cao et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies
- (2019) Fabio Morandi et al. Cells
- Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody
- (2018) Jacinda Ristov et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Clinical trials for myasthenia gravis: a historical perspective
- (2018) Henry J. Kaminski et al. Annals of the New York Academy of Sciences
- Belimumab: A Review in Systemic Lupus Erythematosus
- (2018) Hannah A. Blair et al. DRUGS
- Advances in autoimmune myasthenia gravis management
- (2018) Shuhui Wang et al. Expert Review of Neurotherapeutics
- Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial
- (2018) Sonoko Misawa et al. LANCET NEUROLOGY
- Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
- (2018) Karen Hewett et al. NEUROLOGY
- Advances in autoimmune myasthenia gravis management
- (2018) Shuhui Wang et al. Expert Review of Neurotherapeutics
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
- (2018) Peter Ulrichts et al. JOURNAL OF CLINICAL INVESTIGATION
- Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration
- (2018) Bryan Smith et al. mAbs
- Targeting FcRn to Generate Antibody-Based Therapeutics
- (2018) E. Sally Ward et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Factors affecting outcome in ocular myasthenia gravis
- (2017) Marco Mazzoli et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
- (2017) James F Howard et al. LANCET NEUROLOGY
- Rituximab treatment of myasthenia gravis: A systematic review
- (2017) Rup Tandan et al. MUSCLE & NERVE
- Rituximab as treatment for anti-MuSK myasthenia gravis
- (2017) Michael K. Hehir et al. NEUROLOGY
- High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine
- (2017) Lucy A. McNamara et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- B-cell-activating factor is elevated in serum of patients with myasthenia gravis
- (2016) Sa-Yoon Kang et al. MUSCLE & NERVE
- International consensus guidance for management of myasthenia gravis
- (2016) Donald B. Sanders et al. NEUROLOGY
- Randomized Trial of Thymectomy in Myasthenia Gravis
- (2016) Gil I. Wolfe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
- (2016) Ding Chen et al. Journal of Clinical Medicine
- Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8+ T cell immunity during gammaherpesvirus infection
- (2015) D. F. Pinelli et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Targeting FcRn for the modulation of antibody dynamics
- (2015) E. Sally Ward et al. MOLECULAR IMMUNOLOGY
- The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
- (2015) Nezha Senhaji et al. Frontiers in Immunology
- Central role of interferon-beta in thymic events leading to myasthenia gravis
- (2014) Perrine Cufi et al. JOURNAL OF AUTOIMMUNITY
- Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms
- (2014) Sonia Berrih-Aknin et al. JOURNAL OF AUTOIMMUNITY
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- Genetic Variants in C5 and Poor Response to Eculizumab
- (2014) Jun-ichi Nishimura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study
- (2014) Linda L. Kusner et al. PLoS One
- Reversing Endogenous Alloreactive B Cell GC Responses With Anti-CD154 or CTLA-4Ig
- (2013) J. Chen et al. AMERICAN JOURNAL OF TRANSPLANTATION
- A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
- (2013) James F. Howard et al. MUSCLE & NERVE
- B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
- (2013) Maria J Leandro ARTHRITIS RESEARCH & THERAPY
- Recommendations for myasthenia gravis clinical trials
- (2012) Michael Benatar et al. MUSCLE & NERVE
- Lifetime course of myasthenia gravis
- (2007) David Grob et al. MUSCLE & NERVE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started